정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 646 | Recruiting | Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients | COVID-19 | Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Other: Intravenous saline injection (Placebo) |
Phase 2 | Renmin Hospital of Wuhan University, Beijing SH Bio-Tech Corporation, Beijing (CN), Utooth Biological Technology Co., Ltd. Hubei (CN) | OTHER | 20 | All | 18 Years ~ 65 Years | Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China |
| 645 | Recruiting | Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen | COVID-19 Infection | Drug: Zavegepant (BHV-3500) Drug: Placebo |
Phase 3 | Biohaven Pharmaceuticals, Inc. | INDUSTRY | 120 | All | 18 Years | Georgetown University Medical Center, Washington, District of Columbia, United States Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States Roper Hospital, Charleston, South Carolina, United States |
| 644 | Enrolling by invitation | Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia | COVID-19 | Drug: EXO 1 inhalation Drug: EXO 2 inhalation Drug: Placebo inhalation |
Phase 2 | Olga Tyumina, Clinics of the Federal State Budgetary Educational Institution SSMU, Samara Regional Clinical Hospital V.D. Seredavin | OTHER | 90 | All | 18 Years ~ 65 Years | Medical Centre Dinasty, Samara, Russian Federation |
| 643 | Not yet recruiting | Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19 | Sars-CoV2 | Biological: Mesenchymal Stromal Cells infusion | Phase 1 | Hospital de Clinicas de Porto Alegre | OTHER | 10 | All | ||
| 642 | Recruiting | Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients | SARS CoV-2 | Biological: Human Amniotic Fluid | Phase 2 | University of Utah | OTHER | 60 | All | 18 Years | University of Utah Health, Salt Lake City, Utah, United States |
| 641 | Recruiting | Safety and Immunity of Covid-19 aAPC Vaccine | Treat and Prevent Covid-19 Infection | Biological: Pathogen-specific aAPC | Phase 1 | Shenzhen Geno-Immune Medical Institute, Shenzhen Third People's Hospital, Shenzhen Second People's Hospital | OTHER | 100 | All | 6 Months ~ 80 Years | Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China |
| 640 | Recruiting | Safety and Immunogenicity of a Nipah Virus Vaccine | Nipah Virus Infection | Biological: HeV-sG-V Biological: Normal Saline Placebo |
Phase 1 | Auro Vaccines LLC, PATH, Coalition for Epidemic Preparedness Innovations, Cincinnati Children's Hospital Medical Center (CCHMC) | INDUSTRY | 274 | All | 18 Years ~ 49 Years | Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio, United States |